De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Alkem Laboratories Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Vikas Gupta

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	1.1yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	1.1yrs
Gemiddelde ambtstermijn bestuur	7.1yrs

Recente managementupdates

Recent updates

What Alkem Laboratories Limited's (NSE:ALKEM) P/E Is Not Telling You

Sep 24

Is Alkem Laboratories (NSE:ALKEM) Using Too Much Debt?

Sep 03

Earnings Beat: Alkem Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Aug 13

Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year

Jul 27

Alkem Laboratories' (NSE:ALKEM) Dividend Will Be Reduced To ₹5.00

Jul 13

Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year

Jun 27

Alkem Laboratories (NSE:ALKEM) Has Announced That Its Dividend Will Be Reduced To ₹5.00

Jun 13

Alkem Laboratories Limited (NSE:ALKEM) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Jun 01

Earnings Tell The Story For Alkem Laboratories Limited (NSE:ALKEM)

May 22

Alkem Laboratories Limited (NSE:ALKEM) Just Reported And Analysts Have Been Lifting Their Price Targets

Feb 13

Investors Appear Satisfied With Alkem Laboratories Limited's (NSE:ALKEM) Prospects

Jan 17

These 4 Measures Indicate That Alkem Laboratories (NSE:ALKEM) Is Using Debt Reasonably Well

Sep 20

Alkem Laboratories' (NSE:ALKEM) Dividend Is Being Reduced To ₹4.00

Jul 27

Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year

Jul 13

Does This Valuation Of Alkem Laboratories Limited (NSE:ALKEM) Imply Investors Are Overpaying?

Jun 11

Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?

May 23

Does This Valuation Of Alkem Laboratories Limited (NSE:ALKEM) Imply Investors Are Overpaying?

Mar 06

Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?

Feb 21

Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year

Feb 08

CEO

Vikas Gupta

1.1yrs

Tenure

Dr. Vikas Gupta is Chief Executive Officer of Alkem Laboratories Limited from September 22, 2023. He has experience in Pharmaceutical Sector and brings with him deep experience across therapeutic areas inc...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Basudeo Singh	Executive Chairman	51.2yrs	₹200.60m	13.31% ₹ 97.6b
Sarvesh Singh	VP of Sales & Marketing and Executive Director	no data	₹44.50m	0% ₹ 0
Sandeep Singh	MD & Executive Director	1.1yrs	₹81.50m	0.0065% ₹ 47.9m
Mritunjay Singh	Executive Director	no data	₹104.30m	8.58% ₹ 62.9b
Srinivas Singh	Executive Director	2.1yrs	₹96.60m	0.086% ₹ 629.8m
Madhurima Singh	Executive Director	no data	₹104.10m	8.77% ₹ 64.3b
Vikas Gupta	Chief Executive Officer	1.1yrs	geen gegevens	geen gegevens
Akhilesh Sharma	President & Chief Medical Officer	no data	geen gegevens	geen gegevens
Kaustav Banerjee	President & Head Medtech Business	less than a year	geen gegevens	geen gegevens
Rajorshi Ganguli	President & Global HR Head	no data	geen gegevens	geen gegevens
Nitin Agrawal	CFO & President of Finance	less than a year	geen gegevens	geen gegevens
Satish Singh	Head of Operations	no data	geen gegevens	0.060% ₹ 441.1m

1.1yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ALKEM wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.1 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Basudeo Singh	Executive Chairman	51.2yrs	₹200.60m	13.31% ₹ 97.6b
Sarvesh Singh	VP of Sales & Marketing and Executive Director	4.9yrs	₹44.50m	0% ₹ 0
Sandeep Singh	MD & Executive Director	11.2yrs	₹81.50m	0.0065% ₹ 47.9m
Mritunjay Singh	Executive Director	15.9yrs	₹104.30m	8.58% ₹ 62.9b
Srinivas Singh	Executive Director	2.1yrs	₹96.60m	0.086% ₹ 629.8m
Madhurima Singh	Executive Director	2.8yrs	₹104.10m	8.77% ₹ 64.3b
Arun Purwar	Independent Director	9.6yrs	₹3.30m	geen gegevens
Sudha Ravi	Independent Director	9.3yrs	₹3.10m	geen gegevens
Sangeeta Singh	Independent Director	9.3yrs	₹3.00m	geen gegevens
Narendra Aneja	Independent Director	4.6yrs	₹3.20m	geen gegevens
Rajeev Kher	Independent Director	less than a year	geen gegevens	geen gegevens
Sujjain Talwar	Independent Director	2.2yrs	₹2.70m	geen gegevens

7.1yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ALKEM wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.3 jaar).

Alkem Laboratories Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Alkem Laboratories Limited Announces Retirement of Yogesh Kaushal as Senior Management Personnel

Alkem Laboratories Limited Approves Appointment of Rajeev Kher as an Independent Director

Alkem Laboratories Limited Announces Change in Management

Less than half of directors are independent

Alkem Laboratories Limited, Annual General Meeting, Aug 30, 2024

Alkem Laboratories Limited Announces CFO Changes

Recent updates

Cipla, Alkem Laboratories Reportedly in Final Lap to Buy SMT

Alkem Laboratories Limited Announces Retirement of Yogesh Kaushal as Senior Management Personnel

Alkem Laboratories Limited Approves Appointment of Rajeev Kher as an Independent Director

Alkem Labs Reportedly in Talks to Acquire Novartis India from Its Swiss Parent

What Alkem Laboratories Limited's (NSE:ALKEM) P/E Is Not Telling You

Alkem Reportedly Joins $3 Billion Race for JB Chem as Torrent Pauses Talks

Is Alkem Laboratories (NSE:ALKEM) Using Too Much Debt?

KKR, TPG Capital, Apax Partners and Other PE Firms Reportedly Eye Purchase of Sahajanand Medical Technologies

Earnings Beat: Alkem Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Upcoming dividend of ₹5.00 per share

Full year 2024 earnings: EPS and revenues miss analyst expectations

Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year

Alkem Laboratories Limited to Report Q1, 2025 Results on Aug 09, 2024

Alkem Laboratories' (NSE:ALKEM) Dividend Will Be Reduced To ₹5.00

Alkem Laboratories Limited Announces Change in Management

Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year

Less than half of directors are independent

Alkem Laboratories (NSE:ALKEM) Has Announced That Its Dividend Will Be Reduced To ₹5.00

Biosergen AB Receives the Final Permission Required to Test Lead Candidate BSG005 in Patients with Invasive Fungal Infection

Alkem Laboratories Limited (NSE:ALKEM) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Alkem Laboratories Limited, Annual General Meeting, Aug 30, 2024

Final dividend of ₹5.00 announced

Alkem Laboratories Limited Recommends Final Dividend for Financial Year Ended March 31, 2024, Payable on and from 4 September, 2024

Full year 2024 earnings released: EPS: ₹150 (vs ₹82.31 in FY 2023)

Earnings Tell The Story For Alkem Laboratories Limited (NSE:ALKEM)

Alkem Laboratories Limited to Report Q4, 2024 Results on May 29, 2024

Consensus EPS estimates increase by 10%

Alkem Laboratories Limited (NSE:ALKEM) Just Reported And Analysts Have Been Lifting Their Price Targets

Price target increased by 9.5% to ₹4,523

Third quarter 2024 earnings released: EPS: ₹49.76 (vs ₹38.03 in 3Q 2023)

Alkem Laboratories Limited Approves Interim Dividend for Financial Year 2023-24 , Payable on 1 March, 2024

Investors Appear Satisfied With Alkem Laboratories Limited's (NSE:ALKEM) Prospects

Alkem Laboratories Limited Announces CFO Changes

Alkem Laboratories Limited Announces CFO Changes

We Think Alkem Laboratories (NSE:ALKEM) Can Manage Its Debt With Ease

Alkem Laboratories Limited Appoints Ashish Sehgal to Hold Senior Management Position in the Company Effective 15 December 2023

Alkem Laboratories Limited Submits Clinical Trial Application for First Patient Study with Bsg005 in Invasive Fungal Infections in India as A Rescue Therapy

Alkem Laboratories Limited Appoints Kaustav Banerjee to Hold Senior Management Position

Alkem Laboratories Appoints Sanchit Bansal to Senior Management Position

Alkem Laboratories Limited Appoints Madhurima Singh, Executive Director

Price target increased by 7.5% to ₹3,956

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Alkem Laboratories Limited to Report Q2, 2024 Results on Nov 07, 2023

Alkem Laboratories Limited Appoints Vikas Gupta as the Chief Executive Officer, Effective 22nd September, 2023

Alkem Laboratories Limited Appoints Vikas Gupta as the Chief Executive Officer, Effective 22nd September, 2023

Is Alkem Laboratories (NSE:ALKEM) Using Too Much Debt?

Price target increased by 7.5% to ₹3,612

Upcoming dividend of ₹10.00 per share at 0.6% yield

Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year

Alkem Laboratories Limited to Report Q1, 2024 Results on Aug 10, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year

Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Alkem Laboratories Limited Recommends Final Dividend for Financial Year Ended March 31, 2023, Payable on and from August 30, 2023

Alkem Laboratories Limited, Annual General Meeting, Aug 25, 2023

Alkem Laboratories Limited to Report Q4, 2023 Results on May 19, 2023

We Think Alkem Laboratories (NSE:ALKEM) Can Stay On Top Of Its Debt

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alkem Laboratories Limited Declares Special Dividend for the Financial Year 2022-2023, Payable Be on and from 01 March, 2023

Alkem Laboratories Limited Declares Interim Dividend for the Financial Year 2022-2023, Payable on 1 March 2023

Alkem Laboratories Limited to Report Q3, 2023 Results on Feb 10, 2023

Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?

Eight Roads Ventures India Healthcare IV, L.P entered into a Shareholders’ Agreement to acquire a minority stake in Enzene Biosciences Ltd from Alkem Laboratories Limited (BSE:539523) for INR 1614.83 million.

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

High number of new directors